Forgot Password

Type 1 diabetes cord blood trials

Cord reinfusion in type 1 diabetes (CoRD) pilot study

Australian researchers at The Children’s Hospital at Westmead, in a world first clinical trial (CoRD Study), are investigating the potential to prevent or delay the onset of type 1 diabetes (T1D) in high risk children using a child’s own (autologous) cord blood. This pilot study funded by Cell Care and is open to parents across Australia who have stored (or planning to store) their child’s own (autologous) cord blood. The trial aims to recruit 400-600 participants in the initial screening phase to identify children at high risk of developing T1D. A total of 20 children identified at high risk will be offered reinfusion of their cord blood. Participants will be monitored and followed for up to 3 years. 

Location: Sydney, Australia
Trial design: Pilot study    
Status: Open - currently recruiting 
Find out more

Cord blood infusion for type 1 diabetes mellitus (T1DM)

Researchers in Bavaria, Germany, aim to recruit 23 children from the age of 1 with T1D mellitus to undergo infusion of autologous (their own) cord blood in an attempt to regenerate the insulin producing cells in the pancreas and improve blood glucose control. As secondary goals, the investigators aim to track the migration of transfused cord blood stem cells and study the potential changes in metabolism and immune function leading to islet regeneration. 

Location: Bavaria, Germany
Trial design: Safety and efficacy        
Status: Active – not recruiting 
Find out more